Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Biomarker; Pharmacodynamics
- Acronyms AVA-CELL
- 18 Aug 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 02 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Jun 2015.
- 21 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.